⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL158812 | 0.97 | — | — | |
| SCHEMBL1132942 | 0.97 | — | — | |
| SCHEMBL16765733 | 0.90 | — | — | |
| SCHEMBL8663405 | 0.87 | POLB (0.44) | — | |
| Succinic Acid SCHEMBL29509251 | 0.83 | POLB (0.50) | — | |
| Biphenyl SCHEMBL7894663 | 0.80 | MEN1 (0.48) | — | |
| (Z)-1,2-Diphenylethene SCHEMBL20495486 | 0.76 | MEN1 (0.44) | — | |
| SCHEMBL7614934 | 0.75 | — | — | |
| SCHEMBL12726564 | 0.72 | — | — | |
| SCHEMBL28015858 | 0.71 | LMNA (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2540734-B1 | Process and reagents for oligonucleotide synthesis and purification | ALNYLAM PHARMACEUTICALS INC (US) | 2016-03-30 | — | — | EP | disclosed |
| EP-2899278-A1 | iRNA agents targeting VEGF | Alnylam Pharmaceuticals Inc. (US) | 2015-07-29 | — | — | EP | disclosed |
| US-20150011608-A1 | iRNA Agents Targeting VEGF | ALNYLAM PHARMACEUTICALS, INC. | 2015-01-08 | — | — | US | disclosed |
| EP-2636739-A1 | iRNA agents targeting VEGF | Alnylam Pharmaceuticals Inc. (US) | 2013-09-11 | — | — | EP | disclosed |
| EP-2365077-B1 | iRNA agents targeting VEGF | ALNYLAM PHARMACEUTICALS INC (US) | 2013-05-08 | — | — | EP | disclosed |
| US-8431693-B2 | Process for desilylation of oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20130018085-A1 | iRNA Agents Targeting VEGF | ALNYLAM PHARMACEUTICALS, INC. | 2013-01-17 | — | — | US | disclosed |
| EP-2540734-A2 | Process and reagents for oligonucleotide synthesis and purification | Alnylam Pharmaceuticals, Inc. (US) | 2013-01-02 | — | — | EP | disclosed |
| US-8293719-B2 | iRNA agents targeting VEGF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-10-23 | — | — | US | disclosed |
| US-8063198-B2 | Processes and reagents for desilylation of oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-7851615-B2 | Lipophilic conjugated iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-12-14 | — | — | US | disclosed |
| US-20090187027-A1 | PROCESSES AND REAGENTS FOR SULFURIZATION OF OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| US-20090005549-A1 | Processes and Reagents for Desilylation of Oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| EP-1737878-A2 | PROCESS AND REAGENTS FOR OLIGONUCLEOTIDE SYNTHESIS AND PURIFICATION | Alnylam Pharmaceuticals Inc. (US) | 2007-01-03 | — | — | EP | disclosed |
| EP-1735009-A2 | iRNA AGENTS TARGETING VEGF | Alnylam Pharmaceuticals Inc. (US) | 2006-12-27 | — | — | EP | disclosed |
| US-20060223770-A1 | IRNA agents targeting VEGF | ALNYLAM EUROPE AG (DE) | 2006-10-05 | — | — | US | disclosed |
| US-20060094032-A1 | iRNA agents targeting VEGF | ALNYLAM PHARMACEUTICALS, INC. | 2006-05-04 | — | — | US | disclosed |
| US-20050267300-A1 | Processes and reagents for oligonucleotide synthesis and purification | ALNYLAM PHARMACEUTICALS | 2005-12-01 | — | — | US | disclosed |
| WO-2005097817-A2 | PROCESS AND REAGENTS FOR OLIGONUCLEOTIDE SYNTHESIS AND PURIFICATION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2005-10-20 | — | — | WO | disclosed |
| WO-2005089224-A2 | iRNA AGENTS TARGETING VEGF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2005-09-29 | — | — | WO | disclosed |